GET DAILY SIGNALSAnteris Technologies Global Corp. (AVR) Analyst Targets Suggest +126% Upside from Recent Levels
Key Takeaways
- The central price target is $14, the arithmetic mean of verified analyst targets from Cantor Fitzgerald ($15), TD Cowen ($15), Wells Fargo ($16), and Barclays ($10).
- At a recent price near $6.20, Anteris Technologies Global Corp. (AVR) would need to gain roughly 126% to reach $14 — a very large move for any equity.
- Individual targets span $10 to $16, with three firms at Buy or Overweight and Barclays initiating coverage at Hold.
- Supporting factors include a sharp expected revenue ramp, a substantial cash position, and a differentiated "biomimetic" heart-valve platform.
- Principal risks are deep operating losses, minimal revenue relative to market value, a premium valuation, and dependence on clinical and regulatory milestones.
- For more context on this ticker, explore its Major News, Today's Price Move, Forecast, and Earnings pages.
- Investors seeking AI-driven ideas can also explore Trending AI Robots.
Analyst Price Targets and Consensus View
Anteris Technologies Global Corp. (AVR) is a structural-heart medical-device company, not an ETF. Its lead product is the DurAVR transcatheter heart valve, a "biomimetic" valve designed to treat severe aortic stenosis in a less invasive transcatheter procedure. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Coverage of the stock is thin but current. The most recent, individually attributable targets are Cantor Fitzgerald at $15 (Overweight), TD Cowen at $15 (Buy), Wells Fargo at $16 (Overweight), and Barclays at $10 (Hold, initiated by Matt Miksic in October 2026). Averaging those four figures yields a mean of $14, which matches the roughly $14 average reported by S&P Global and MarketBeat across a $10-to-$16 range. The central target used here is therefore $14.
The spread is wide for a stock this size, reflecting genuine disagreement about how quickly Anteris can convert clinical progress into commercial revenue. The bullish targets lean on the valve's differentiated design and an expected inflection in sales, while the more cautious Barclays view reflects the still-early commercial stage and ongoing losses.
Current Market Position and Path Toward the Target
AVR recently traded near $6.20, with a market capitalization of roughly $600 million. Reaching $14 implies an upside of about 126%, which is a very large required move. Notably, the stock has already shown outsized volatility — its 52-week range extends from about $3.30 to roughly $11.06 — so the path, if it materializes, would likely be uneven rather than linear.
Anteris is essentially pre-scale. Trailing-twelve-month revenue is only about $2.3 million against a net loss near $108 million and negative EPS of roughly -$1.95. The investment case therefore rests on future execution rather than current profitability: analysts model revenue rising to roughly $7 million in 2026 and above $10 million in 2027, with the company holding about $233 million in cash to fund development.
What Could Support a Move Toward the Target
- Differentiated technology. DurAVR is engineered to mimic a healthy native aortic valve, a design distinction from competing transcatheter valves that could support adoption if clinical data remain positive.
- Revenue inflection. A projected jump from about $1.9 million in 2025 toward $7 million in 2026 would mark the beginning of commercial scaling, a catalyst analysts cite in their Buy ratings.
- Balance sheet. A cash position near $233 million provides runway to fund trials and commercialization without immediate dilution pressure.
- Analyst positioning. Four of the named firms rate the stock Buy or Overweight, with target revisions generally holding at or above $15.
What Could Prevent the Target From Being Reached
- Persistent losses. Negative EPS and a net loss near $108 million mean the company is not yet self-funding.
- Premium valuation. With minimal revenue, the stock trades at an elevated price-to-sales multiple, leaving little room for disappointment.
- Execution and regulatory risk. Clinical-trial outcomes, regulatory decisions, and commercial launch execution are binary-style risks for early-stage medical-device companies.
- Volatility. A 52-week range from $3.30 to $11.06 shows the shares can reprice sharply on single data points or financing news.
Technical Levels and Market Structure
The most relevant technical reference is the 52-week high near $11.06. A sustained move toward $14 would first require clearing that prior peak, making it a meaningful resistance zone. The $10 round-number level, which coincides with Barclays' target, also acts as a psychological marker. On the downside, the $5.50-to-$6.00 area has served as a recent consolidation zone, with the low near $3.30 representing a deeper support level. The long-term structure is best described as a high-volatility uptrend punctuated by sharp drawdowns.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, and the figures cited here are consistent with that convention, though individual firms may frame their outlooks differently. Investors should monitor quarterly earnings (the next results follow the company's November reporting cycle), any updates to full-year revenue guidance, clinical data releases and regulatory milestones for DurAVR, analyst target revisions, and cash-burn trajectory. No definitive forecast or timing should be inferred from the target itself.
Final Assessment
The central target of $14 is the arithmetic mean of current analyst targets spanning $10 to $16. It represents a roughly 126% move from a recent price near $6.20 — a very large advance that hinges almost entirely on Anteris converting its DurAVR platform into accelerating commercial revenue. The strongest supports are a differentiated valve design, a projected revenue inflection, and a healthy cash balance; the principal obstacles are sustained losses, a premium valuation, and binary clinical and regulatory risks. Analyst disagreement is meaningful, and the target is an expectation, not a guarantee. Investors should focus on revenue execution, clinical data, and cash burn rather than the price level itself.
Using AI Daily Buy/Sell Signals for Additional Perspective
In my own workflow, Tickeron's AI Daily Buy/Sell Signals provide a helpful layer of systematic monitoring for names like this. The tool applies artificial intelligence to track thousands of stocks and ETFs, generating signals based on market conditions and technical behavior. For a volatile, event-driven stock, it can surface opportunities and trend shifts efficiently alongside fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AVR's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for AVR turned positive on October 28, 2026. Looking at past instances where AVR's MACD turned positive, the stock continued to rise in 11 of 12 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AVR's RSI Indicator exited the oversold zone, 5 of 6 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 14 of 16 cases where AVR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
Following a +6.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where AVR advanced for three days, in 92 of 104 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
AVR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AVR as a result. In 19 of 24 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The 50-day moving average for AVR moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AVR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for AVR entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. AVR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.206) is normal, around the industry mean (4.142). P/E Ratio (-2.918) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (238.095) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AVR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement